FDA Approves Eli Lilly's Multi-Dose Zepbound Pen for Weight Loss

Key Facts

1The US FDA approved a multi-dose injection pen for Eli Lilly's weight-loss drug Zepbound.

2The new pen delivers four weekly injections from a single device.

3The drug will be available at the same self-pay price as the single-dose vial format.

Eli Lilly has received US Food and Drug Administration (FDA) approval for a multi-dose injection pen for its weight-loss medication, Zepbound. The newly approved device delivers four weekly injections from a single pen, significantly improving patient convenience and treatment adherence. According to the company, the drug will be offered at the same self-pay price as the existing single-dose vial format. This strategic move aims to streamline the delivery of high-demand weight-loss treatments within the competitive GLP-1 market. Analysts view this approval as a positive development that could enhance Eli Lilly's market share and operational efficiency. The introduction of the multi-dose pen is expected to provide a competitive edge for LLY as it continues to scale its obesity franchise.